>MNTA – The one that didn't work out was the other lmwh, I can't remember the name. It's not listed on the mnta pipeline chart so I assume its dead.<
The defunct program is dalteparin a.k.a. Fragmin, which MNTA canned because the branded drug has been a commercial flop.
Unlike Lovenox, which is approved for both acute and chronic indications, Fragmin is approved only for acute indications (with the exception of treating DVT secondary to cancer).
Market Data 
Markets 
AI
